Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00705757 · ClinicalTrials.gov registry record · Phase 4
The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye
A Phase 4 study, sponsored by Summa Health System.
- Completed
- Registry status
- Phase 4
- Development phase
- 89
- Enrollment target
NCT00705757 is a Phase 4 study that has completed, run by Summa Health System. The registered enrollment target is 89 participants.
The verdict
NCT00705757, a Phase 4 study, has completed, sponsored by Summa Health System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 89 participants
- Enrollment target
Study Summary
The purpose of this study is to study changes in skin color that may be caused by using one of the three eye medicines: Xalatan, Travatan or Lumigan.
Interventions
- DRUG latanoprost
- DRUG bimatoprost
- DRUG travoprost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2008-03 |
| Est. Completion | 2011-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00705757
The ClinicalTrials.gov registry entry for NCT00705757 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Summa Health System, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which latanoprost is the first listed.
NCT00705757 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00705757 about?
NCT00705757 is a clinical study titled "The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye". The purpose of this study is to study changes in skin color that may be caused by using one of the three eye medicines: Xalatan, Travatan or Lumigan.
What is the current status of trial NCT00705757?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 89 participants. The study started on 2008-03. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00705757?
The interventions under investigation include: latanoprost (DRUG), bimatoprost (DRUG), travoprost (DRUG).
Who is sponsoring clinical trial NCT00705757?
This trial is sponsored by Summa Health System, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.